Pharmacokinetic Study of Vivitrol in Healthy Participants
Status:
Enrolling by invitation
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
This is a Phase I, single-center, single arm, open-label study, to establish the
pharmacokinetic (PK) parameters of Vivitrol 380 mg IM injection (IP), a US Food and Drug
Administration (FDA) approved medication.
Phase:
Phase 1
Details
Lead Sponsor:
Go Medical Industries Pty Ltd
Collaborators:
Clinilabs, Inc. Columbia University National Institute on Drug Abuse (NIDA) New York State Psychiatric Institute